- Home
- PPBT
PPBT
Purple Biotech Ltd.
as 04-24-2025 12:42pm EST
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
| Founded: | 2010 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.1M | IPO Year: | N/A |
| Target Price: | $33.00 | AVG Volume (30 days): | 15.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.00 - $20.60 | Next Earning Date: | 05-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Purple Biotech Ltd. News
PPBT Breaking Stock News: Dive into PPBT Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
GlobeNewswire
23 days ago
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
GlobeNewswire
a month ago
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
GlobeNewswire
a month ago
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
2 months ago
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
GlobeNewswire
2 months ago
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
GlobeNewswire
3 months ago
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
GlobeNewswire
5 months ago
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Compare PPBT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PPBT Purple Biotech Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.